MindWalk Files Patent for AI Drug Discovery Data Layer

Key takeaway

• MindWalk, a biotech AI company, filed a European patent for the data layer that powers its drug-discovery AI tools.

• The patent protects the structured biological representation that lets AI models and agents retrieve and reason over connected biology with traceable context.

• As AI models become commodities, the company believes lasting competitive advantage will shift to the data infrastructure layer, a market opportunity projected to grow as spending on AI in drug discovery rises from approximately US$5 billion（約8000億円） in 2026 to more than US$8 billion（約1.3兆円） by 2030.

3 Key Points

FAQ

What does MindWalk's new patent cover?

The patent application EP26187897.9 covers high-dimensional data structures for biological subsequences and property inference, protecting the enriched biological representation architecture that underpins HYFT® Technology, ReefIQ™, and LensAI™. It protects a distinct computational layer that organizes biological meaning around characteristic patterns into a form that can be reused across MindWalk's infrastructure and customer programs.

What is the market opportunity for AI in drug discovery?

Spending on AI in drug discovery is projected to grow from approximately US$5 billion（約8000億円） in 2026 to more than US$8 billion（約1.3兆円） by 2030, and it sits atop the more than US$250 billion（約40兆円） the pharmaceutical industry invests in research and development each year.

How does this filing differ from MindWalk's earlier patent?

The new application builds on MindWalk's foundational HYFT patent (EP3881326A1), which established how the company identifies characteristic biological patterns and uses them as a searchable language. The new filing protects a distinct and additive layer—the computational layer built on that original foundation—rather than a re-filing.